Wolbachia in filarial parasites: Targets for filarial infection and disease control

Current Infectious Disease Reports

Volumn 9, Issue 1, 2007, Pages 55-59

  Johnston, Kelly L ^b   Taylor, Mark J ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; DOXYCYCLINE; IVERMECTIN; LIPOSOME; MYELOID DIFFERENTIATION FACTOR 88; PLACEBO; RIFAMPICIN; TETRACYCLINE; TOLL LIKE RECEPTOR 2; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

AFRICA; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL GENE; BLINDNESS; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TARGETING; ENDOSYMBIOSIS; FILARIASIS; HUMAN; INFECTION CONTROL; NONHUMAN; ONCHOCERCIASIS; PATHOGENESIS; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WOLBACHIA;

EID: 33846978768     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0023-2     Document Type: Review

References (34)

1. Molyneux DH, Bradley M, Hoerauf A, et al.: Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol 2003, 19:516-522.
2. Borsboom GJ, Boatin BA, Nagelkerke NJ, et al.: Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J 2003, 2:8.
3. Dadzie Y, Neira M, Hopkins D: Final report of the Conference on the eradicability of Onchocerciasis. Filaria J 2003, 2:2.
4. Stolk WA, Swaminathan S, van Oortmarssen GJ, et al.: Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis 2003, 188:1371-1381.
5. Michael E, Malecela-Lazaro MN, Simonsen PE, et al.: Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis 2004, 4:223-234.
6. Awadzi K, Attah SK, Addy ET, et al.: Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004, 98:359-370.
7. Awadzi K, Boakye DA, Edwards G, et al.: An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004, 98:231-249.
8. Taylor MJ, Bandi C, Hoerauf A: Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol 2005, 60:245-284.
9. Fenn K, Blaxter M: Are filarial nematode Wolbachia obligate mutualist symbionts? Trends Ecol Evol 2004, 19:163-166.
10. Foster J, Ganatra M, Kamal I, et al.: The Wolbachia genome of Brugia malayi: endosymbiont evolution within a human pathogenic nematode. PLoS Biology 2005, 3:e121.
11. Pfarr K, Hoerauf A: The annotated genome of Wolbachia from the filarial nematode Brugia malayi: what it means for progress in antifilarial medicine. PLoS Med 2005, 2:e110.
12. Fenn K, Blaxter M: Wolbachia genomes: revealing the biology of parasitism and mutualism. Trends Parasitol 2006, 22:61-65.
13. Heider U, Blaxter M, Hoerauf A, Pfarr KM: Differential display of genes expressed in the filarial nematode Litomosoides sigmodontis reveals a putative phosphate permease up-regulated after depletion of Wolbachia endobacteria. Int J Med Microbiol 2006, 296:287-299.
14. Townson S, Tagboto S, McGarry HF, et al.: Onchocerca parasites and Wolbachia endosymbionts: evaluation of a spectrum of antibiotic types for activity against Onchocerca gutturosa in vitro. Filaria J 2006, 5:4.
15. Ghedin E, Wang S, Foster JM, Slatko BE: First sequenced genome of a parasitic nematode. Trends Parasitol 2004, 20:151-153.
16. Rao R, Moussa H, Vanderwaal RP, et al.: Effects of gamma radiation on Brugia malayi infective larvae and their intracellular Wolbachia bacteria. Parasitol Res 2005, 97:219-227.
17. Rao RU, Atkinson LJ, Vanderwall RP, Weil GJ: Brugia malayi: effects of gamma radiation on adult worms and their intracellular Wolbachia bacteria. Exp Parasitol 2005, 109:87-93.
18. Hoerauf A, Satoguina J, Saeftel M, Specht S: Immunomodulation by filarial nematodes. Parasite Immunol 2005, 27:417-429.
19. Gillette-Ferguson I, Hise AG, McGarry HF, et al.: Wolbachia-induced neutrophil activation in a mouse model of ocular onchocerciasis (river blindness). Infect Immun 2004, 72:5687-5692.
20. Gillette-Ferguson I, Hise AG, Sun Y, et al.: Wolbachia- and Onchocerca volvulus-induced keratitis (river blindness) is dependent on myeloid differentiation factor 88. Infect Immun 2006, 74:2442-2445.
21. Higazi TB, Filiano A, Katholi CR, et al.: Wolbachia endosymbiont levels in severe and mild strains of Onchocerca volvulus. Mol Biochem Parasitol 2005, 141:109-112.
22. Turner JD, Langley RS, Johnston KL, et al.: Wolbachia endosymbiotic bacteria of Brugia malayi mediate macrophage tolerance to TLR- and CD40-specific stimuli in a MyD88/TLR2-dependent manner. J Immunol 2006, 177:1240-1249.
23. Debrah AY, Mand S, Specht S, et al.: Doxycycline reduces plasma VEGF-C/ sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2006, 2:e92.
24. Fenollar F, Maurin M, Raoult D: Wolbachia pipientis growth kinetics and susceptibilities to 13 antibiotics determined by immunofluorescence staining and real-time PCR. Antimicrob Agents Chemother 2003, 47:1665-1671.
25. Makepeace BL, Rodgers L, Trees AJ: Rate of elimination of Wolbachia pipientis by doxycycline in vitro increases following drug withdrawal. Antimicrob Agents Chemother 2006, 50:922-927.
26. Taylor MJ, Makunde WH, McGarry HF, et al.: Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 2005, 365:2116-2121.
27. Hoerauf A, Mand S, Fischer K, et al.: Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol (Berl) 2003, 192:211-216.
28. Debrah AY, Mand S, Marfo-Debrekyei Y, et al.: Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin. Filaria J 2006, 5:1.
29. Hoerauf A, Mand S, Volkmann L, et al.: Doxycycline in the treatment of human onchocerciasis: Kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect 2003, 5:261-273.
30. Turner JD, Mand S, Debrah AY, et al.: A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin Infect Dis 2006, 42:1081-1089.
31. Stolk WA, de Vlas SJ, Habbema JD: Anti-Wolbachia treatment for lymphatic filariasis. Lancet 2005, 365:2067-2068.
32. Volkmann L, Fischer K, Taylor M, Hoerauf A: Antibiotic therapy in murine filariasis (Litomosoides sigmodontis): comparative effects of doxycycline and rifampicin on Wolbachia and filarial viability. Trop Med Int Health 2003, 8:392-401.
33. Bajpai P, Vedi S, Owais M, et al.: Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model. J Drug Target 2005, 13:375-381.
34. Gilbert J, Nfon CK, Makepeace BL, et al.: Antibiotic chemotherapy of onchocerciasis: in a bovine model, killing of adult parasites requires a sustained depletion of endosymbiotic bacteria (Wolbachia species). J Infect Dis 2005, 192:1483-1493.